Consulting
for effective life science R&D and partnering
Haberman
Associates is a Boston-based consulting firm, founded in 1993, that specializes
in science and technology strategy for life science companies.
We
assist your company to achieve its business goals in new product development and
commercialization. Our focus is on effective R&D, business development, and
partnering.
Clients have used our consulting services to
help them:
- discover and develop new drugs, diagnostics,
and research products
- improve their drug pipelines
- identify
and evaluate potential partners
- develop new applications for their technologies
- penetrate new markets
For additional
information about how we can assist your company, please see "About
Haberman Associates". Or use our site map
to navigate our entire site.
For an initial discussion
of your company's needs, or if you have any questions about our firm, please contact
us.
Haberman Associates is a member of the Biopharmaceutical
Consortium, an expert team of consultancies formed in 1997 to assist life
science companies, research groups, and emerging enterprises.It is also an Affiliate
of Innovalyst,
a consulting consortium that helps life science companies to make better business
decisions, accelerates the development of innovations, and catalyzes commercial
success.
June 4, 2010: The Biopharmconsortium
Blog has moved to our own site. See our News
Page.
March 16, 2010: “Reducing Attrition
In Silico” published in Bio-IT World. See our News
Page.
March 5, 2010: Animal Models for
Therapeutic Strategies published by Cambridge Healthtech Institute. See
our News Page.
September
11, 2009: Haberman Associates joins Innovalyst as an Affiliate. See our News
Page.
September 11, 2009: Dr. Haberman quoted in article
on the Bristol-Myers Squibb/Medarex deal in Nature Biotechnology. See our News
Page.
August 3, 2009: Our article on Phase II Attrition
featured on Page One of the August issue of Genetic Engineering News. See our
News Page or the PDF.
May
5, 2009: Approaches to Reducing
Phase II Attrition published by Cambridge Healthtech Institute.
See our News Page.
Our online
articles:
"Overcoming
Phase II Attrition Problem"
(Published in the August 2009 issue of
Genetic Engineering News.)
"Strategies
to Overcome Blood-Brain Barrier"
(Published in the February 1, 2009
issue of Genetic Engineering News.)
"Addressing
Unmet Type 2 Diabetes Needs"
(Published in the January 1, 2008 issue
of Genetic Engineering News.)
"Recent
Clinical Developments in Type 2 Diabetes: Preventing Diabetes and Preventing Cardiovascular
Events in Diabetics"
(Published in the October 19, 2006 issue of
CHI's Pharma DD.)
"Safety
Issues Hamper Dual PPAR Agonists: Is Partial Antagonism the Solution?"
(Published in the September 22, 2006 issue of CHI's Pharma DD.)
"Breaking
the Obesity Barrier: Near-Term Prospects for Breakthrough Treatments"
(Published in the December 22, 2005 issue of CHI's PharmaWeek.)
"Strategies
to Move Beyond Target Validation: Targets and Druggability for Small
and
Large Molecule Drugs"
(Published in the December 1, 2005 issue of
Genetic Engineering News.)
"Therapeutic
Strategies in Animal Models: the Case of Alzheimer's Disease."
(Published
in the September 15, 2004 issue of Genetic Engineering News.)
